| Aug 8 |
Gilead (GILD) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
|
| Aug 8 |
Gilead Sciences, Inc. 2024 Q2 - Results - Earnings Call Presentation
|
| Aug 8 |
Gilead Hikes Profit Outlook As Biggest HIV Drug Outperforms Expectations
|
| Aug 8 |
Gilead Sciences (GILD) Q2 Earnings and Revenues Beat Estimates
|
| Aug 8 |
Gilead quarterly results beat on both lines and raises full-year non-GAAP EPS outlook
|
| Aug 8 |
Gilead Sciences in charts: Revenue from HIV, liver disease, and oncology therapies advances in Q2
|
| Aug 8 |
Gilead Boosts Earnings Outlook as Stock Battles Back from Cancer Disappointment
|
| Aug 8 |
Gilead: Q2 Earnings Snapshot
|
| Aug 8 |
Gilead quarterly profit beats Street estimates, revenue up 5%
|
| Aug 8 |
Gilead Sciences Non-GAAP EPS of $2.01 beats by $0.41, revenue of $6.95B beats by $210M
|
